Tigilanol tiglate
A drug used for the treatment of certain types of cancer
Tigilanol tiglate is a pharmaceutical drug used in the treatment of certain types of cancer. It is a diterpene ester derived from the seeds of the plant Fontainea picrosperma, commonly known as the blushwood tree, which is native to the rainforests of Queensland, Australia.
Mechanism of Action[edit | edit source]
Tigilanol tiglate works by activating protein kinase C (PKC), a family of enzymes that play a crucial role in regulating cell growth and apoptosis. The activation of PKC by tigilanol tiglate leads to the rapid destruction of tumor cells through a process known as oncolytic necrosis. This process involves the disruption of the tumor's blood supply, leading to tumor cell death and subsequent immune-mediated clearance of the tumor debris.
Clinical Use[edit | edit source]
Tigilanol tiglate is primarily used in the treatment of non-metastatic cutaneous and subcutaneous tumors. It has been approved for veterinary use under the trade name Stelfonta for the treatment of mast cell tumors in dogs. The drug is administered as a direct intratumoral injection, which allows for localized treatment of the tumor with minimal systemic exposure.
Development and Research[edit | edit source]
Research into tigilanol tiglate has been ongoing since its discovery in the seeds of the blushwood tree. Preclinical studies demonstrated its efficacy in inducing tumor regression in various animal models. Clinical trials in humans are being conducted to evaluate its safety and efficacy in treating different types of cancer, including melanoma and squamous cell carcinoma.
Side Effects[edit | edit source]
The administration of tigilanol tiglate can lead to localized side effects at the site of injection, including swelling, redness, and ulceration. Systemic side effects are rare due to the localized nature of the treatment. In veterinary use, the drug has been well-tolerated, with most side effects being mild and self-limiting.
Future Directions[edit | edit source]
Ongoing research aims to expand the use of tigilanol tiglate to other types of cancer and to explore its potential in combination with other therapeutic modalities, such as immunotherapy and chemotherapy. The unique mechanism of action of tigilanol tiglate makes it a promising candidate for further development in the field of oncology.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD